CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project Summary This R21 pilot grant aims to benchmark single-lineage RNA-Seq (slRNA-Seq), an innovative technology that enables transcriptome analysis of microbial lineages with sensitivity far exceeding current single-microbe methods. Current approaches for bacterial RNA-seq are severely limited by technical challenges including short mRNA half-lives, absence of poly-A tails, and small transcript numbers. We established an approach using “Capsules with Amphiphilic Gel Envelopes” (CAGEs) that allows clonal expansion of individual cells followed by multi-step in-capsule library preparation, dramatically improving transcript detection to thousands of genes per lineage while efficiently capturing CRISPR interference perturbations. Building on this, this pilot grant will evaluate the broad utility of slRNA-Seq through two specific aims: (1) evaluate bacterial PERTURB-Seq by optimizing library preparation protocols and generating a benchmark dataset of all transcription factor perturbations in E. coli; and (2) develop slRNA-Seq as a tool for host- pathogen interaction profiling through co-encapsulation of human immune cells with microbial populations. Our specific focus will be on detecting immune cell transcriptional responses alongside pathogen identity in each CAGE and evaluating that CAGEs are not perturbative to immune cells or their response. We propose multiple strategies to optimize CAGEs and slRNA-Seq if we identify challenges during the pilot. This technology directly addresses NIAID priorities for tools to systematically dissect host-pathogen responses. If successful, this project will establish slRNA-Seq as a robust platform for bacterial functional genomics and microbiome research, providing the scientific community with transformative tools to investigate previously intractable questions about microbial gene function and host-pathogen interactions.
Grant Summary
CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $296K for university, nonprofit, healthcare org. Applications are due 2028-04-30 (open). Check eligibility and apply with FindGrants.
Not quite the right fit?
Search 9,000+ open grants, or get matches ranked for your organization — free.
Focus Areas
Eligibility
How to Apply
Up to $296K
2028-04-30
- 1Confirm your organization is eligible for CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis: Frequently Asked Questions
Who is eligible for the CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis?
CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis provide?
CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis provides up to $296K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis deadline?
Applications for CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis are due 2028-04-30 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis?
To apply for CAGE-Enabled Single-Lineage RNA-Seq for Bacterial PERTURB-Seq and Host-Pathogen Interaction Analysis, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.